Skip to main
RAPP
RAPP logo

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc has seen notable momentum in its stock performance following its inaugural R&D Day and the positive Phase 2a data released on September 8. The data from the Phase 2a trial, involving 30 patients with refractory focal onset epilepsy, indicates a significantly improved therapeutic window for their candidate drug, RAP-219, supported by earlier preclinical and Phase 1 studies. The rapid and substantial control of seizures demonstrated by RAP-219 suggests a strong potential for success in upcoming Phase 3 trials, indicating a commercially competitive profile even with a conservative estimate of efficacy.

Bears say

Rapport Therapeutics Inc faces a challenging outlook due to concerns regarding the efficacy estimates from its Phase 2a trial, where the exclusion of patients from the analysis raises doubts about the robustness of these results and may lead to lower efficacy in Phase 3 trials. Furthermore, even with potential regulatory approval, the company's market position could be adversely affected by significant competition and unfavorable insurance coverage, limiting the commercial viability of its drugs. These factors contribute to apprehensions about the company's financial future and overall stock performance.

RAPP has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Strong Buy based on their latest research and market trends.

According to 3 analysts, RAPP has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.